USA - engelsk - NLM (National Library of Medicine)

pharmaceutical associates, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. there are no known contraindications to the use of sucralfate.

USA - engelsk - NLM (National Library of Medicine)

precision dose inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

USA - engelsk - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. there are no known contraindications to the use of sucralfate.

USA - engelsk - NLM (National Library of Medicine)

stat rx usa llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate is an α-d-glucopyranoside, β-d-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. tablets for oral administration contain 1 g of sucralfate. also contain: povidone, magnesium stearate, and colloidal silicon dioxide. therapeutic category: antiulcer. sucralfate is only minimally absorbed from the gastrointestinal tract. the small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. although the mechanism of sucralfate’s ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. the following observations also appear pertinent: - studies in human subjects and with animal models of ulcer disease have shown that sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site. - in vitro , a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions. - in human subjects, sucralfate given in doses recomme

USA - engelsk - NLM (National Library of Medicine)

a-s medication solutions - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate tablets, usp are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

USA - engelsk - NLM (National Library of Medicine)

bryant ranch prepack - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

USA - engelsk - NLM (National Library of Medicine)

atlantic biologicals corp. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

USA - engelsk - NLM (National Library of Medicine)

pinnacle pharma llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oralsuspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oralsuspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

USA - engelsk - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate tablets are indicated in:  - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.  sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.